Last week’s authorization by the U.S. Food and Drug Administration for emergency use of bamlanivimab feels like a shot in the arm, so to speak, for Dr. David Wohl, a UNC infectious diseases physician and researcher. A monoclonal antibody developed … Read more

A long-acting injectable drug, cabotegravir, is safe and more effective than a daily pill in preventing HIV acquisition, according to results from a study of 3,127 cisgender women in sub-Saharan Africa. Led by UNC researchers beginning in November 2017, the … Read more

Human beings will continue to suffer from infectious diseases, some of them contagious. To fight a new disease, infectious disease physicians first work to define the rules that govern the disease, its spread and the gravity of the infection. Those … Read more

A team of researchers led by UNC Project-Malawi has received a one-year, $500,000 grant to build clinical and research capacity in Malawi to better diagnose and treat children with sickle cell disease. The funding is a joint award from the … Read more

The expanding COVID-19 pandemic has transformed the social lives of people across the world. A collaboration between researchers at the UNC Institute for Global Health & Infectious Disease, the London School of Hygiene and Tropical Medicine, and the Academic Network for … Read more

Irving Hoffman, international director of the Institute’s UNC Project-Malawi, offers this report as the country recorded its first death from COVID-19. Despite limited testing, Malawi has recorded 10 COVID-19 cases with one death and some evidence of community spread. UNC … Read more

Doctor Linghua Li is an infectious disease specialist and AIDS clinic director at Eighth People’s Hospital in Guangzhou, China. She completed two years of postdoctoral training in infectious diseases at Duke University and at UNC-Chapel Hill, working with David Wohl … Read more

The Institute for Global Health and Infectious Diseases and UNC Project-Malawi were awarded a $4.5 million grant by the U.K.’s Fleming Fund to strengthen Malawi’s One Health Antimicrobial Resistance (AMR) program. The grant will support the national AMR coordination committee and … Read more

Researchers from the University of North Carolina at Chapel Hill, in partnership with colleagues at other sites in the U.S., Europe and Australia, will receive up to $10.7 million from the National Institutes of Health to move closer to identifying a vaccine candidate for chlamydia, the most prevalent bacterial sexually transmitted infection in the world.

The world’s first vaccine for malaria will be tested in a pilot study beginning this month in three countries with a high burden of the disease among children, according to researchers leading the project from the University of North Carolina at Chapel Hill and UNC Project-Malawi.